News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

RYAN W. STEVENS, PHARMD, BCIDP, BCPS

Advertisement

Articles by RYAN W. STEVENS, PHARMD, BCIDP, BCPS

Exploring Primary Prophylaxis for Invasive Pulmonary Aspergillosis

ByRYAN W. STEVENS, PHARMD, BCIDP, BCPS,KAITE KAMMERS, PHARMD, BCPS
December 11th 2018

Invasive aspergillosis affects up to 13% of immunocompromised patients who are in the hospital.

Advertisement

Latest Updated Articles

  • Exploring Primary Prophylaxis for Invasive Pulmonary Aspergillosis
    Exploring Primary Prophylaxis for Invasive Pulmonary Aspergillosis

    Published: December 11th 2018 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

Opioid Use Linked to Nearly Double the Risk of C difficile Infection

2

FDA Approves GSK’s Gepotidacin for Gonorrhea

3

Working With Young Clinicians to Identify, Treat Vector-Borne Diseases

4

FDA Plans to Review Already Approved RSV Immunizations

5

‘Complicating the Decision-Making’ for the Universal Birth Dose of the Hepatitis B Vaccine

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us